YIH
KNTE

Y-Intercept (HK)’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Y-Intercept (HK)’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,410
Closed -$43.6K – 1847
2023
Q4 		$43.6K Buy
+18,410
New +$32.6K ﹤0.01% 1168
2023
Q3 		– Sell
-33,702
Closed -$102K – 1753
2023
Q2 		$102K Buy
+33,702
New +$130K 0.01% 1094

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Y-Intercept (HK)'s KNTE Position: Q1 2024 in Review

Y-Intercept (HK) sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 18,410 shares — an estimated $43.6K sold.

Y-Intercept (HK) first reported a position in KNTE in Q2 2023 and held it in 2 quarters. The position peaked at $102K in Q2 2023. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • Y-Intercept (HK) reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 18,410 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $43.6K.
  • Y-Intercept (HK) first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Kinnate Biopharma Inc. Common Stock position peaked at $102K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.